Join
Live feed
·
PRReleasevia Quantisnow
Arrowhead Pharmaceuticals Inc. logo
Royalty Pharma plc logo

Royalty Pharma Agrees to Acquire Royalty Interest in Olpasiran From Arrowhead for $250 million and Future Milestones

ByQuantisnow·Wall Street's wire, on your screen.
ARWR· Arrowhead Pharmaceuticals Inc.RPRX· Royalty Pharma plc
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ARWR (Arrowhead Pharmaceuticals Inc.), RPRX (Royalty Pharma plc) and more on Quantisnow.